DENVER, Oct. 15 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
(Amex: AXK) and SCHOTT Nexterion AG (Mainz, Germany) announced today the
signing of a supply agreement and a letter of intent to proceed to an
exclusive technology transfer license for Accelr8's OptiChem(TM) surface
chemistry products. Under the supply agreement, SCHOTT Nexterion will
purchase Accelr8's OptArray(TM) microarraying slides and re-sell them under
the Nexterion brand through its global sales organization starting
immediately. Under the intended technology transfer license, SCHOTT Nexterion
will manufacture the OptArray slides and have exclusive global marketing
rights to these products. The two companies will cooperatively market the
products, and Accelr8 will provide technology transfer consulting services to
facilitate the transition.
Accelr8 will be SCHOTT Nexterion's sole supplier of permeable hydrogel
microarraying slides during the term of the supply agreement. Accelr8 will
provide sales training and will provide technical support to SCHOTT
Nexterion's customers. Accelr8's microarraying slides complement SCHOTT
Nexterion's existing product range by providing a permeable three-dimensional
hydrogel surface for high-performance applications in basic research, drug
discovery, and molecular diagnostics. During the term of the supply agreement
Accelr8 will continue to produce the microarraying products in its Denver
facility. It is intended that SCHOTT Nexterion will ultimately become the
exclusive outsource manufacturer for OptArray products in the Summer of 2004.
Accelr8 will use exclusively SCHOTT's borosilicate glass in its slides, as it
optimally complements the performance of the OptiChem surface chemistry.
Thomas Geimer, Accelr8's Chairman and CEO said "This agreement represents
the first step in fulfilling our objective of licensing our proprietary
technologies to microarray market leaders. SCHOTT Nexterion has aggressively
entered the microarray market through strategic investments and acquisitions.
They are the type of partner we've been seeking to help drive the next phase
of microarray market evolution with our enabling technologies. This
relationship will leverage our proven product superiority in the DNA array
market and build the foundation for protein arraying."
According to Dr. Dirk van den Broek, CEO of SCHOTT Nexterion, "We are very
pleased to adopt Accelr8's hydrogel technology at this critical juncture in
the DNA microarraying market. We intend to address the growing interest in
improving microarray reproducibility and data quality. Our scientists have
confirmed the superior consistency and signal-to-noise performance that
OptiChem coatings can deliver, and so we believe that this technology puts us
in position to advance microarrays to their next level."
Geimer noted "The intended license also validates our business model of
licensing our technologies into partnerships with market leaders. The license
will allow us to focus on expanding OptiChem's capabilities. In addition we
will be able to commit more of our resources to the next generation of
detection platforms that we believe can replace fluorescence detection."
About Accelr8 Technology.
Accelr8 Technology Corporation ( www.accelr8.com ) is a developer of
innovative materials and instrumentation for advanced bio-analytical
applications in basic research, drug discovery, molecular diagnostics, and
pathogen detection for bio-defense and food safety. The company sells
OptArray(TM) microarraying slides and OptiPlate(TM) multiplexed arrayable
microtiter plates. It is also developing advanced detection instrumentation
based on its QuanDx(TM) and YoDx(TM) array processing and detection
About SCHOTT Nexterion.
SCHOTT Nexterion AG ( www.schott.com/nexterion ), a wholly owned
subsidiary of SCHOTT, is specialized in high quality microarray solutions. As
such, the company develops and markets a wide range of coated and uncoated
glass substrates for DNA and protein microarraying. SCHOTT Nexterion
continuously expands its product portfolio and has several innovative products
and services in the development pipeline. SCHOTT is an international
technology-driven group and has 19,500 employees producing worldwide sales of
2 billion euros.
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Statements regarding future prospects and developments are based
upon current expectations and involve certain risks and uncertainties that
could cause actual results and developments to differ materially from the
forward-looking statement, including those detailed in the company's filings
with the Securities and Exchange Commission.
SOURCE Accelr8 Technology Corporation